Evaluate of clinical efficacy of autologous serum therapy
- Conditions
- Diseases of the skin and subcutaneous tissue
- Registration Number
- KCT0001969
- Lead Sponsor
- Ajou University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
1.Adult patients with recalcitrant atopic dermatitis (age = 13 years) whose clinical conditions has not been effectively controlled by current standard medical therapies for more than 2 months
2.=10% lesion body surface area (BSA) of atopic dermatitis involvement in area at the screening and baseline visits
Exclusion criteria
1) Patients under the age of 13 year.
2) Patients who are unable to agree on their own (emergency patients, patients with mental disability, patients with limited capacity to consent due to stroke or delirium caused by diabetes).
3) Patients with severe disease whose expected survival duration is less than 3 months.
4) Pregnancy or planned pregnancy within 1 year
5) Skin condition not appropriate for blood sampling and transfusion
6) Presence of skin comorbidities that may interfere with study assessments
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients with both a reduction of clinical severity scores by = 30% or =50% from baseline.
- Secondary Outcome Measures
Name Time Method Safety verification;Blood test parameters (serum immunoglobulin, allergen-specific IgE, IgG autoantibodies, serum eosinophil cationic protein, cytokine, etc);Requirement for medication;Quality of life measured before and after the treatment